COMS

GTC is proud to present our 2nd Annual Ubiquitin Research and Drug Development Conference! This meeting, taking place on February 27-28, 2012 at the Red Rock Resort & Spa in Las Vegas, NV, will bring together leaders from biotech and pharmaceutical companies, academia, and government, to provide you with a solid primer for a better understanding of the complex activities of ubiquitin and ubiquitin-like proteins and some solutions to the challenges associated with ubiquitin drug development.

Therefore, 3D cell culture technologies and associated analytical tools are essential for basic and pharmaceutical research as well as for the evaluation of chemicals and cosmetics.

This 2.5-day symposium covers the newest developments in the key areas of 3D cell culture technologies. This comprises advanced 3D cell culture models for efficacy and safety studies, enabling technologies to create and analyze biological reactions as well as their successful implementation in compound de-risking.

The 6th Biomarker Development Conference offers attendees insight into the latest developments from the leading players will offering a unique networking opportunity.

Offering a unique opportunity, the Biomarker Partnering and Deal-Making Conference assembles leading players to discuss what needs to be accomplished to lead the industry into its next phase. The business of biomarkers has reached an exciting and critical stage and intelligence and strategic relationship building is more important than ever. Attendees will be able to set the stage for both at this leading event.

This symposium will be of interest to analytical, pharmaceutical and regulatory scientists involved in pharmaceutical research, development and manufacturing. It will be of particular interest to scientists and managers engaged in analytical development or quality control, where advances in analytical technologies and practices can enhance productivity, problem-solving or quality-by-design capabilities.

HDL Satellite meetings are an established feature of the triennial ISA meetings and regularly attract many of the leading researchers in the field.

The objective of this HDL satellite symposium is to provide a forum for presentation and discussion of state-of-the-art knowledge of the biology and biochemistry of high-density lipoprotein (HDL) and of recent developments in therapeutics directed to modifications of HDL metabolism and function. The program will reflect the many recent exciting developments in this field and will include invited presentations by many leading researchers in the field. Additional oral presentations will be selected from submitted abstracts and poster sessions will also form an integral part of the scientific program.

Antibiotics, more than any other medicines, have improved the life expectancy of mankind, however, multi-drug resistance has become common in pathogenic bacteria and the “magic bullets” are losing efficacy. Recent reports on the occurrence of panresistant gram-negative strains, i.e. strains resistant to every registered antibacterial drug, indicate that we are on the verge to lose the battle, taking us back to the pre-antibiotic era. There is world-wide consensus that the medical need for novel antiinfective drugs is enormous and that we are running out of time. Many achievements of modern medicine, not only treatment of infectious diseases, depend on the availability of efficacious antibiotics, still, the antibacterial development pipeline is drying up and the number of new drugs reaching the market is alarmingly low. There are many reasons for this at all levels of the discovery and development process. Major investments into research and technologies did not pay off; socioeconomic considerations together with regulatory hurdles have prompted big pharma to exit the field and innovative biotech companies were confronted with problems beyond their control. Answers are needed as to where and how we can find new lead compounds with unprecedented activities? How to bridge substantial gaps between academic and industry with translational research? How to make antibiotic development a profitable business?

The “New Antibacterial Discovery & Development" GRC seeks to analyze the current situation and to identify answers. It will provide an international forum for researchers of multiple backgrounds to exchange ideas and discuss their views of the problems, to present most recent discoveries and technologies and thus to contribute to the future availability of life-saving antibiotic drugs.

Chemistry is playing an increasingly pivotal role and chemists are often intimately involved at the forefront of the biological sciences whilst bringing to them the distinctive approaches of the rigorous chemical sciences.

The Symposium will also highlight the key role of chemistry in the discovery and development of new therapeutic agents for human diseases.